Antibodies against human CSF-1R and uses thereof
The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
1. An antibody binding to human CSF-1R, wherein the antibody is the deposited antibody DSM ACC2920.
2. An antibody binding to human CSF-1R, or an antigen-binding fragment thereof, wherein:
a) the antibody, or antigen-binding fragment thereof, comprises a heavy chain variable domain comprising a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6, or
b) the antibody, or antigen-binding fragment thereof, comprises a heavy chain variable domain comprising a CDR3 region of SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 10, and a CDR1 region of SEQ ID NO: 11, and a light chain variable domain comprising a CDR3 region of SEQ ID NO:12, a CDR2 region of SEQ ID NO: 13, and a CDR1 region of SEQ ID NO: 14.
3. The antibody, or antigen-binding fragment thereof, according to of claim 1 , wherein said antibody is of human IgG4 subclass or is of human IgG1 subclass.
4. A pharmaceutical composition comprising the antibody, or antigen-binding fragment thereof, according to claim 1 .
5. The antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antibody is a CDR grafted, humanized, T cell epitope depleted, chimeric, single chain, or multispecific antibody.
6. The antibody, or antigen-binding fragment thereof, of claim 1 , wherein the heavy chain variable domain comprising a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and the light chain variable domain comprising a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6.
7. The antibody, or antigen-binding fragment thereof, of claim 1 , wherein the heavy chain variable domain comprising a CDR3 region of SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 10, and a CDR1 region of SEQ ID NO: 11, and the light chain variable domain comprising a CDR3 region of SEQ ID NO:12, a CDR2 region of SEQ ID NO: 13, and a CDR1 region of SEQ ID NO: 14.